Tell me all about rifagut tablet
Reading File
Finding Sources
Searching the Web
Rifagut rifaximin tablet uses dosage mechanism side effects
Searching PubMed
rifaximin clinical uses efficacy
Reading File
Reading File
Searching PubMed
rifaximin hepatic encephalopathy IBS traveler diarrhea
I now have comprehensive information to deliver a thorough answer. Here is everything about Rifagut tablet:
Rifagut Tablet (Rifaximin) - Complete Overview
What Is Rifagut?
Rifagut is a branded formulation of Rifaximin, manufactured by Sun Pharma in India. It belongs to the rifamycin class of antibiotics but is unique because it is virtually non-absorbable - acting almost entirely within the gastrointestinal tract. It is available in three strengths: 200 mg, 400 mg, and 550 mg tablets.
Mechanism of Action
Rifaximin works by inhibiting bacterial RNA synthesis - it binds to the beta subunit of DNA-dependent RNA polymerase, blocking transcription and preventing bacteria from making proteins essential for growth and reproduction. It is active against a broad spectrum of organisms:
- Gram-positive aerobes and anaerobes
- Gram-negative aerobes and anaerobes
The key pharmacological feature is its minimal systemic absorption (<0.5% orally). This results in:
- Very high fecal drug concentrations (up to 8,000 mcg/g after a 3-day course)
- Negligible plasma levels
- Low systemic toxicity
(Katzung's Basic and Clinical Pharmacology, 16th Ed.)
Approved Uses / Indications
1. Traveler's Diarrhea
- Caused by non-invasive strains of E. coli
- Used in patients aged 12 years and older
- Dose: 200 mg three times daily for 3 days
- Note: Not recommended for diarrhea complicated by fever or bloody stool (may indicate invasive organisms)
2. Irritable Bowel Syndrome with Diarrhea (IBS-D)
- FDA-approved for IBS-D in adults
- Dose: 550 mg three times daily for 14 days
- Also used at 400 mg three times daily for 10 days in some protocols
- Meta-analysis of 5 studies: rifaximin was significantly better than placebo for global IBS symptom improvement (OR 1.57; 95% CI 1.22-2.01; NNT = 10.2) and for bloating (OR 1.59; 95% CI 1.23-1.96; NNT = 10)
- Up to two retreatment courses may be given for recurrence
- Both the ACG and AGA conditionally recommend it (evidence grade 2B)
- (Yamada's Textbook of Gastroenterology, 7th Ed.)
3. Hepatic Encephalopathy (HE)
- Used to reduce the risk of recurrent episodes of overt HE in adults with liver disease
- Kills ammonia-producing bacteria in the gut, lowering blood ammonia levels
- Dose: 550 mg twice daily (ongoing, indefinite use)
- Often combined with lactulose for additive effect
- Rifaximin acts by modulating intestinal microbial function rather than composition
- (Yamada's Textbook of Gastroenterology, 7th Ed.; Harrison's Principles of Internal Medicine, 22nd Ed.)
4. Off-label / Occasional Uses
- Recurrent or refractory Clostridioides difficile infection - as an adjunct (rifaximin is active against C. difficile; no change in susceptibility noted after retreatment courses)
- Small intestinal bacterial overgrowth (SIBO)
- Diverticular disease prevention - cyclic rifaximin + fiber reduces recurrence (10.4% vs 19.3% on fiber alone)
- Spontaneous bacterial peritonitis (SBP) prophylaxis - evidence still limited
Dosage Summary
| Indication | Dose | Duration |
|---|---|---|
| Traveler's diarrhea | 200 mg 3x/day | 3 days |
| IBS-D | 550 mg 3x/day | 14 days |
| Hepatic encephalopathy | 550 mg 2x/day | Long-term / ongoing |
| SIBO | 400 mg 3x/day | 10 days |
Can be taken with or without food.
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Absorption | <0.5% - essentially non-systemic |
| Distribution | Remains in GI lumen |
| Metabolism | Minimal systemic metabolism |
| Excretion | Feces (>96%) |
| Fecal concentration | ~8,000 mcg/g after 3-day course |
Important: In patients with hepatic impairment, systemic exposure is markedly elevated compared to healthy subjects - use with caution.
Side Effects
Common:
- Nausea, vomiting
- Flatulence (excessive gas)
- Abdominal pain / cramping
- Headache
- Dizziness
- Peripheral edema (swelling of hands/feet)
- Fatigue / tiredness
- Diarrhea (paradoxically)
- Dry mouth
Serious (rare):
- Severe allergic reactions - anaphylaxis, angioedema, exfoliative dermatitis
- Clostridioides difficile - associated diarrhea (rare; one case in retreatment trial)
- Abnormal liver function tests
(Goldman-Cecil Medicine, International Ed.)
Drug Interactions
Due to minimal absorption, rifaximin has a very low potential for drug interactions (unlike other rifamycins such as rifampicin). Key points:
- Does NOT significantly induce CYP3A4 at recommended doses in patients with normal liver function (in vitro induction noted but not clinically relevant at standard doses)
- Warfarin: Increased INR and bleeding risk reported - monitor INR closely if used together; dose adjustment of warfarin may be needed
- Ketoconazole: May increase rifaximin blood concentrations, especially in liver impairment
- P-glycoprotein inhibitors may increase rifaximin exposure
Contraindications
- Hypersensitivity to rifaximin, any rifamycin antibiotic, or product components
- Diarrhea with fever or bloody stool (may indicate invasive organisms - rifaximin is not effective against invasive pathogens)
- Use with caution in severe hepatic impairment (Child-Pugh C) due to elevated systemic exposure
Special Populations
| Population | Consideration |
|---|---|
| Pregnancy | Category C - use only if clearly needed |
| Lactation | Unknown if excreted in breast milk - caution advised |
| Renal impairment | No specific dose adjustment data; generally safe given minimal absorption |
| Hepatic impairment | Systemic exposure significantly elevated - use cautiously |
| Children <12 years | Not established for traveler's diarrhea; not studied for IBS-D/HE |
Key Advantages of Rifaximin Over Other Antibiotics
- Non-systemic - acts locally in the gut, minimizing systemic side effects
- Broad spectrum - covers gram-positive, gram-negative, aerobes, and anaerobes
- No CYP-P450 interactions at standard doses (unlike rifampicin)
- Low resistance development in typical therapeutic courses
- Preserves gut microbiome more than systemic antibiotics - modest, transient changes only
Brand Substitutes (India)
- Faxicad 550 mg (Cadila Pharmaceuticals)
- Rafle 550 mg (Alembic)
- Rixmin 550 mg (Cipla)
- Torfix 550 mg (Torrent)
- Zimigut 550 mg (Intas)
Important Patient Counseling Points
- Complete the full course even if symptoms improve
- Avoid alcohol - increases risk of side effects
- Stay well hydrated
- Report bloody or black stools, severe rash, or worsening symptoms immediately
- Inform your doctor about all medications, especially warfarin
- Do not drive if you feel dizzy
Sources: Katzung's Basic & Clinical Pharmacology (16th Ed.) | Yamada's Textbook of Gastroenterology (7th Ed.) | Goldman-Cecil Medicine | Harrison's Principles of Internal Medicine (22nd Ed.) | Practo drug profile | Apollo Hospitals
This is a shared conversation. Sign in to Orris to start your own chat.